These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 20847177)

  • 1. Complementary roles of whole-body diffusion-weighted MRI and 18F-FDG PET: the state of the art and potential applications.
    Kwee TC; Takahara T; Ochiai R; Koh DM; Ohno Y; Nakanishi K; Niwa T; Chenevert TL; Luijten PR; Alavi A
    J Nucl Med; 2010 Oct; 51(10):1549-58. PubMed ID: 20847177
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Newly diagnosed lymphoma: initial results with whole-body T1-weighted, STIR, and diffusion-weighted MRI compared with 18F-FDG PET/CT.
    van Ufford HM; Kwee TC; Beek FJ; van Leeuwen MS; Takahara T; Fijnheer R; Nievelstein RA; de Klerk JM
    AJR Am J Roentgenol; 2011 Mar; 196(3):662-9. PubMed ID: 21343511
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Detection of metastatic lesions from malignant pheochromocytoma and paraganglioma with diffusion-weighted magnetic resonance imaging: comparison with 18F-FDG positron emission tomography and 123I-MIBG scintigraphy.
    Takano A; Oriuchi N; Tsushima Y; Taketomi-Takahashi A; Nakajima T; Arisaka Y; Higuchi T; Amanuma M; Endo K
    Ann Nucl Med; 2008 Jun; 22(5):395-401. PubMed ID: 18600417
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Whole-body diffusion-weighted imaging vs. FDG-PET for the detection of non-small-cell lung cancer. How do they measure up?
    Chen W; Jian W; Li HT; Li C; Zhang YK; Xie B; Zhou DQ; Dai YM; Lin Y; Lu M; Huang XQ; Xu CX; Chen L
    Magn Reson Imaging; 2010 Jun; 28(5):613-20. PubMed ID: 20418042
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evolving role of 18F-FDG-PET/CT for the body tumor and metastases in pediatrics.
    Chen Z; Li X; Li F; Ouyang Q; Yu T
    Eur J Radiol; 2010 Sep; 75(3):329-35. PubMed ID: 20576385
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Increased (18)F-fluorodeoxyglucose uptake in benign, nonphysiologic lesions found on whole-body positron emission tomography/computed tomography (PET/CT): accumulated data from four years of experience with PET/CT.
    Metser U; Even-Sapir E
    Semin Nucl Med; 2007 May; 37(3):206-22. PubMed ID: 17418153
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Whole-body diffusion-weighted imaging: the added value to whole-body MRI at initial diagnosis of lymphoma.
    Gu J; Chan T; Zhang J; Leung AY; Kwong YL; Khong PL
    AJR Am J Roentgenol; 2011 Sep; 197(3):W384-91. PubMed ID: 21862763
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Does positron emission tomography data acquisition impact simultaneous diffusion-weighted imaging in a whole-body PET/MRI system?
    Buchbender C; Hartung-Knemeyer V; Heusch P; Heusner TA; Beiderwellen K; Wittsack HJ; Kühl H; Forsting M; Bockisch A; Antoch G; Lanzman RS
    Eur J Radiol; 2013 Feb; 82(2):380-4. PubMed ID: 23238361
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 18F-FDG PET/CT, 99mTc-MIBI, and MRI in evaluation of patients with multiple myeloma.
    Fonti R; Salvatore B; Quarantelli M; Sirignano C; Segreto S; Petruzziello F; Catalano L; Liuzzi R; Rotoli B; Del Vecchio S; Pace L; Salvatore M
    J Nucl Med; 2008 Feb; 49(2):195-200. PubMed ID: 18199607
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Diffusion-weighted imaging as part of hybrid PET/MRI protocols for whole-body cancer staging: does it benefit lesion detection?
    Buchbender C; Hartung-Knemeyer V; Beiderwellen K; Heusch P; Kühl H; Lauenstein TC; Forsting M; Antoch G; Heusner TA
    Eur J Radiol; 2013 May; 82(5):877-82. PubMed ID: 23428414
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A prospective diagnostic accuracy study of 18F-fluorodeoxyglucose positron emission tomography/computed tomography, multidetector row computed tomography, and magnetic resonance imaging in primary diagnosis and staging of pancreatic cancer.
    Kauhanen SP; Komar G; Seppänen MP; Dean KI; Minn HR; Kajander SA; Rinta-Kiikka I; Alanen K; Borra RJ; Puolakkainen PA; Nuutila P; Ovaska JT
    Ann Surg; 2009 Dec; 250(6):957-63. PubMed ID: 19687736
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PET/CT for the staging and follow-up of patients with malignancies.
    Poeppel TD; Krause BJ; Heusner TA; Boy C; Bockisch A; Antoch G
    Eur J Radiol; 2009 Jun; 70(3):382-92. PubMed ID: 19406595
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Whole-body magnetic resonance imaging and positron emission tomography-computed tomography in oncology.
    Schmidt GP; Kramer H; Reiser MF; Glaser C
    Top Magn Reson Imaging; 2007 Jun; 18(3):193-202. PubMed ID: 17762383
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 18F-FDG PET and CT/MRI in oral cavity squamous cell carcinoma: a prospective study of 124 patients with histologic correlation.
    Ng SH; Yen TC; Liao CT; Chang JT; Chan SC; Ko SF; Wang HM; Wong HF
    J Nucl Med; 2005 Jul; 46(7):1136-43. PubMed ID: 16000282
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of whole body positron emission tomography/computed tomography scan with 18F-fluorodeoxyglucose in patients with biopsy proven tumor metastases from unknown primary site.
    Pelosi E; Pennone M; Deandreis D; Douroukas A; Mancini M; Bisi G
    Q J Nucl Med Mol Imaging; 2006 Mar; 50(1):15-22. PubMed ID: 16557200
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In-line (18)F-fluorodeoxyglucose positron emission tomography with computed tomography (PET/CT) in patients with carcinoma of the sinus/nasal area and orbit.
    Wild D; Eyrich GK; Ciernik IF; Stoeckli SJ; Schuknecht B; Goerres GW
    J Craniomaxillofac Surg; 2006 Jan; 34(1):9-16. PubMed ID: 16343913
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical role of 18F-FDG PET/CT in the management of squamous cell carcinoma of the head and neck and thyroid carcinoma.
    Quon A; Fischbein NJ; McDougall IR; Le QT; Loo BW; Pinto H; Kaplan MJ
    J Nucl Med; 2007 Jan; 48 Suppl 1():58S-67S. PubMed ID: 17204721
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Value of 18F-FDG and 11C-MET PET-CT in differentiation of brain ringlike-enhanced neoplastic and non-neoplastic lesions on MRI imaging].
    Cai L; Gao S; Li DC; Li YS; Chen QS; Xing XL
    Zhonghua Zhong Liu Za Zhi; 2009 Feb; 31(2):134-8. PubMed ID: 19538892
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Early detection of cancer recurrence: 18F-FDG PET/CT can make a difference in diagnosis and patient care.
    Israel O; Kuten A
    J Nucl Med; 2007 Jan; 48 Suppl 1():28S-35S. PubMed ID: 17204718
    [TBL] [Abstract][Full Text] [Related]  

  • 20. (18)F-FDG-PET/CT of orofacial tumors, a value of whole-body imaging approach.
    Ferda J; Ferdová E; Záhlava J; Walter J; Mukensnabl P; Daum O; Kreuzberg B
    Eur J Radiol; 2010 Feb; 73(2):241-8. PubMed ID: 19101104
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.